Compare Carvana Co (CVNA) vs Davita Inc (DVA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Carvana Co vs Davita Inc — how do they compare? Carvana Co trades at $63.55 (market cap $69.07B), while Davita Inc trades at $175.04 (market cap $11.28B). The key difference: Carvana Co is far larger — about 6.1× Davita Inc's market cap, and Davita Inc is trading nearer its 52-week high, Carvana Co nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Carvana Co for 28 Days and Davita Inc for 113 Days on average.
| CVNA | DVA | |
|---|---|---|
Market Cap | $69.07B | $11.28B |
Volume | 6,556,641 | 650,294 |
Sector | Consumer Cyclical | Health |
52-Week High | $95.69 | $240.96 |
52-Week Low | $56.27 | $103.87 |
Typical Hold Time | 28 Days | 113 Days |
Enterprise Value | $71.55B | $24.00B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Carvana (CVNA) trades at $63.21, down 1.02% on the day, with a bearish technical signal from moving averages. The company reported strong fundamentals, including Q2 2026 EPS of $0.42 beating estimates, revenue growth to $20.32B in 2025, and a net income margin of 6.26%. Recent news highlights robust sales performance, with Jefferies noting September unit sales 40% above estimates. Cash flow trends show positive operational growth, though high debt levels and an elevated EV/EBITDA of 503.9 pose concerns.
The outlook for CVNA is mixed; strong revenue growth and operational improvements support upside potential, with a consensus price target of $84.07 implying significant appreciation. However, risks include high valuation multiples, substantial long-term debt of $5.26B, and bearish technical indicators. Investors should weigh robust earnings beats against volatility and leverage concerns.
DaVita (DVA) trades at $177.02, down 1.87% on the day, showing mixed technical signals with a bearish moving average trend but neutral oscillators. Fundamentally, the company demonstrates strong earnings beats with Q2 2026 EPS of $4.02 exceeding expectations of $3.88, while revenue growth continues from $13.64B in 2025 to projected $14.0B in 2026. Recent developments include expanding value-based care partnerships with Humana, potentially benefiting over 10,000 Medicare Advantage members.
The outlook remains cautiously optimistic with 43% analyst buy ratings and a $235.67 consensus price target suggesting 33% upside. However, rising debt-to-asset ratios (65.55% in 2025) and margin pressures from Q2 2026 create headwinds. Key risks include regulatory changes in healthcare reimbursement and competitive pressures in dialysis services.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Carvana Co
Carvana Co is an e-commerce platform for buying and selling used cars. The company derives revenue from used vehicle sales, wholesale vehicle sales and other sales and revenues. The other sales and revenues include sales of loans originated and sold in securitization transactions or to financing partners, commissions received on VSCs and sales of GAP waiver coverage.
Read more on CVNA →About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →
